Evidence map›Paper›PMID 27300430›Full record

ArticleCancer cell2016

Pancreatic Cancer: Planning Ahead for Metastatic Spread.

Ingunn M Stromnes, Philip D Greenberg

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Human pancreatic cancer progression: an anarchy among CCN-siblings.Journal of cell communication and signaling · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ingunn M StromnesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: istromne@fredhutch.org.
Philip D GreenbergClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: pgreen@uw.edu.

Funding

Mechanisms of Murine Turmor Eradication by ImmunotherapyR01CA033084 · NCI · UNIVERSITY OF WASHINGTON · PI GREENBERG, PHILIP D · 1986 to 2017
$5.8M
NCI NIH HHS R01 CA033084
6 · The paper itself

Abstract

Metastasis and therapy resistance are cardinal features of pancreatic ductal adenocarcinoma, a commonly lethal malignancy. In this issue of Cancer Cell, Steele et al. show that CXCR2 expression and neutrophils are required for metastasis. In mice treated with advanced disease, inhibiting both CXCR2 and PD1 cooperatively but not individually prolongs survival.

Indexed as

AdenocarcinomaAnimalsCarcinoma, Pancreatic DuctalPancreatic Neoplasms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.